BMO Capital Starts NewAmsterdam Pharma Co NV (NAMS) at Outperform
BMO Capital initiates coverage on NewAmsterdam Pharma Co NV (NASDAQ: NAMS) with a Outperform rating and a price target of $58.00.
For an analyst ratings summary and ratings history on NewAmsterdam Pharma Co NV click here. For more ratings news on NewAmsterdam Pharma Co NV click here.
Shares of NewAmsterdam Pharma Co NV closed at $31.68 yesterday.